ATE395083T1 - Verfahren zur behandlung von multipler sklerose durch hemmung der il-17-aktivität - Google Patents
Verfahren zur behandlung von multipler sklerose durch hemmung der il-17-aktivitätInfo
- Publication number
- ATE395083T1 ATE395083T1 AT04798568T AT04798568T ATE395083T1 AT E395083 T1 ATE395083 T1 AT E395083T1 AT 04798568 T AT04798568 T AT 04798568T AT 04798568 T AT04798568 T AT 04798568T AT E395083 T1 ATE395083 T1 AT E395083T1
- Authority
- AT
- Austria
- Prior art keywords
- activity
- multiple sclerosis
- inhibiting
- treating multiple
- prophylaxis
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0327181A GB0327181D0 (en) | 2003-11-21 | 2003-11-21 | Biological products |
GB0417115A GB0417115D0 (en) | 2004-07-30 | 2004-07-30 | Biological products |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE395083T1 true ATE395083T1 (de) | 2008-05-15 |
Family
ID=34635441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04798568T ATE395083T1 (de) | 2003-11-21 | 2004-11-16 | Verfahren zur behandlung von multipler sklerose durch hemmung der il-17-aktivität |
Country Status (16)
Country | Link |
---|---|
US (2) | US20070269428A1 (de) |
EP (3) | EP1687026B1 (de) |
JP (1) | JP4833850B2 (de) |
AT (1) | ATE395083T1 (de) |
AU (1) | AU2004292393C1 (de) |
CA (1) | CA2544920C (de) |
CY (1) | CY1116992T1 (de) |
DE (1) | DE602004013825D1 (de) |
DK (1) | DK1983000T3 (de) |
ES (2) | ES2554645T3 (de) |
HR (1) | HRP20151210T1 (de) |
HU (1) | HUE026260T2 (de) |
PL (1) | PL1983000T3 (de) |
PT (1) | PT1983000E (de) |
SI (1) | SI1983000T1 (de) |
WO (1) | WO2005051422A1 (de) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1013141A (en) * | 1960-12-30 | 1965-12-15 | Secr Aviation | Improvements in or relating to the stabilisation of electronic oscillators |
US20070160576A1 (en) * | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
US20040219150A1 (en) * | 2003-02-06 | 2004-11-04 | Cua Daniel J. | Uses of mammalian cytokine; related reagents |
SI2784084T2 (sl) | 2003-07-08 | 2024-02-29 | Novartis Pharma Ag | Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
EP3808769A1 (de) | 2005-12-13 | 2021-04-21 | Eli Lilly And Company | Anti-il-17-antikörper |
EP1976874A1 (de) * | 2005-12-22 | 2008-10-08 | Laboratoires Serono S.A. | Lösliche il-17rc-variante und anwendungen davon |
CA2646478A1 (en) | 2006-03-10 | 2007-09-20 | Zymogenetics, Inc. | Antibodies that bind both il-17a and il-17f and methods of using the same |
US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
US7790163B2 (en) | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
GB0612928D0 (en) * | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
BRPI0715917A2 (pt) | 2006-08-11 | 2014-11-25 | Schering Corp | Anticorpos para il-17a |
GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
EP2216047A4 (de) | 2007-10-24 | 2011-12-28 | Nat Univ Corp Tokyo Med & Dent | Regulator zur signalisierung des toll-like-rezeptors mit einem cathepsin-inhibitor als wirkstoff |
WO2009082624A2 (en) * | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
NZ623706A (en) | 2008-05-05 | 2015-12-24 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
BRPI0919531A2 (pt) | 2008-09-29 | 2015-12-08 | Roche Glycart Ag | anticorpos contra il17 humana e usos dos mesmos |
WO2010062858A1 (en) * | 2008-11-26 | 2010-06-03 | Allergan, Inc. | Il-17 antibody inhibitor for treating dry eye |
WO2010062857A1 (en) | 2008-11-26 | 2010-06-03 | Allergan, Inc. | Klk-13 antibody inhibitor for treating dry eye |
BRPI1014544B8 (pt) | 2009-05-05 | 2021-05-25 | Novimmune Sa | anticorpo anti-il-17f monoclonal totalmente humano isolado e composição farmacêutica compreendendo o mesmo |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
CA2772162C (en) * | 2009-08-27 | 2018-05-22 | Covagen Ag | Anti-il-17a fynomers and medical uses thereof |
US20130046015A1 (en) * | 2010-02-11 | 2013-02-21 | Robert C. Axtell | Therapeutic Inhibition of Granulocyte Function in Demyelinating Disease |
GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
US10208349B2 (en) * | 2011-01-07 | 2019-02-19 | Ucb Biopharma Sprl | Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy |
SG191906A1 (en) | 2011-01-14 | 2013-08-30 | Ucb Pharma Sa | Antibody molecules which bind il-17a and il-17f |
ES2549638T3 (es) | 2011-02-28 | 2015-10-30 | F. Hoffmann-La Roche Ag | Proteínas de unión a antígeno |
CN103403025B (zh) | 2011-02-28 | 2016-10-12 | 弗·哈夫曼-拉罗切有限公司 | 单价抗原结合蛋白 |
BR112014024903A2 (pt) | 2012-04-05 | 2017-07-11 | Hoffmann La Roche | anticorpos biespecíficos contra tweak humanao e il17 humana e seus usos |
WO2014155278A2 (en) * | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
WO2014161570A1 (en) | 2013-04-03 | 2014-10-09 | Roche Glycart Ag | Antibodies against human il17 and uses thereof |
WO2015052230A1 (en) | 2013-10-11 | 2015-04-16 | F. Hoffmann-La Roche Ag | Multispecific domain exchanged common variable light chain antibodies |
UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
KR20180039726A (ko) * | 2015-09-04 | 2018-04-18 | 더 캘리포니아 인스티튜트 포 바이오메디칼 리써치 | 인슐린 면역글로불린 융합 단백질 |
EP3150637A1 (de) | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Multispezifische antikörper |
RU2680011C2 (ru) | 2016-04-29 | 2019-02-14 | Закрытое Акционерное Общество "Биокад" | Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы |
GB2561352B (en) * | 2017-04-10 | 2023-01-18 | Genome Res Ltd | Animal models and therapeutic molecules |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4475196A (en) * | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) * | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) * | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5677425A (en) * | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
EP0768377A1 (de) | 1988-09-02 | 1997-04-16 | Protein Engineering Corporation | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
US5312335A (en) * | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5807683A (en) | 1992-11-19 | 1998-09-15 | Combichem, Inc. | Combinatorial libraries and methods for their use |
US6274711B1 (en) * | 1993-06-14 | 2001-08-14 | Inserm, Institut National De La Sante Et De La Recherche Medicale | Purified mammalian CTLA-8 antigens and related reagents |
US6562333B1 (en) | 1993-06-14 | 2003-05-13 | Schering Corporation | Purified mammalian CTLA-8 antigens and related reagents |
JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
PT744958E (pt) | 1994-01-31 | 2003-11-28 | Univ Boston | Bancos de anticorpos policlonais |
US5738996A (en) | 1994-06-15 | 1998-04-14 | Pence, Inc. | Combinational library composition and method |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
WO1997004097A2 (en) | 1995-07-19 | 1997-02-06 | Genetics Institute, Inc. | Human ctla-8 and uses of ctla-8-related proteins |
US6074849A (en) | 1995-07-19 | 2000-06-13 | Genetics Institute, Inc. | Polynucleotides encoding human CTLA-8 related proteins |
JP2978435B2 (ja) * | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
GB9720054D0 (en) | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
PT1897947E (pt) | 1999-12-23 | 2012-03-29 | Genentech Inc | Polipéptidos homólogos de il-17 e suas utilizações terapêuticas |
US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
MXPA04001187A (es) | 2001-08-07 | 2004-07-08 | Immunex Corp | Receptores de interleucina-1 en el tratamiento de enfermedades. |
DK1576011T3 (da) * | 2002-10-30 | 2009-11-30 | Genentech Inc | Inhibering af IL-17 produktion |
WO2004083249A2 (en) | 2003-03-14 | 2004-09-30 | Wyeth | Antibodies against human il-21 receptor and uses therefor |
DE602004030341D1 (de) | 2003-06-23 | 2011-01-13 | Genetics Inst Llc | Antikörper gegen interleukin-22 und verwendungen dafür |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
WO2005003169A2 (en) | 2003-07-01 | 2005-01-13 | Celltech R & D Limited | Modified antibody fab fragments |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
EP3808769A1 (de) | 2005-12-13 | 2021-04-21 | Eli Lilly And Company | Anti-il-17-antikörper |
-
2004
- 2004-11-16 CA CA2544920A patent/CA2544920C/en not_active Expired - Fee Related
- 2004-11-16 EP EP04798568A patent/EP1687026B1/de not_active Revoked
- 2004-11-16 EP EP15183030.4A patent/EP2974742A1/de not_active Withdrawn
- 2004-11-16 PL PL08008814T patent/PL1983000T3/pl unknown
- 2004-11-16 HU HUE08008814A patent/HUE026260T2/en unknown
- 2004-11-16 US US10/580,164 patent/US20070269428A1/en not_active Abandoned
- 2004-11-16 JP JP2006540587A patent/JP4833850B2/ja not_active Expired - Fee Related
- 2004-11-16 AU AU2004292393A patent/AU2004292393C1/en not_active Ceased
- 2004-11-16 ES ES08008814.9T patent/ES2554645T3/es active Active
- 2004-11-16 DK DK08008814.9T patent/DK1983000T3/en active
- 2004-11-16 EP EP08008814.9A patent/EP1983000B1/de active Active
- 2004-11-16 PT PT80088149T patent/PT1983000E/pt unknown
- 2004-11-16 ES ES04798568T patent/ES2305879T3/es active Active
- 2004-11-16 WO PCT/GB2004/004850 patent/WO2005051422A1/en active IP Right Grant
- 2004-11-16 AT AT04798568T patent/ATE395083T1/de not_active IP Right Cessation
- 2004-11-16 SI SI200432278T patent/SI1983000T1/sl unknown
- 2004-11-16 DE DE602004013825T patent/DE602004013825D1/de active Active
-
2008
- 2008-11-24 US US12/277,030 patent/US7931900B2/en not_active Expired - Fee Related
-
2015
- 2015-11-11 HR HRP20151210TT patent/HRP20151210T1/hr unknown
- 2015-11-30 CY CY20151101086T patent/CY1116992T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1983000A2 (de) | 2008-10-22 |
SI1983000T1 (sl) | 2015-12-31 |
US20070269428A1 (en) | 2007-11-22 |
EP2974742A1 (de) | 2016-01-20 |
US20090191200A1 (en) | 2009-07-30 |
CY1116992T1 (el) | 2017-04-05 |
ES2305879T3 (es) | 2008-11-01 |
AU2004292393B2 (en) | 2009-10-08 |
DE602004013825D1 (de) | 2008-06-26 |
PT1983000E (pt) | 2015-12-30 |
JP4833850B2 (ja) | 2011-12-07 |
EP1983000A3 (de) | 2011-07-27 |
ES2554645T3 (es) | 2015-12-22 |
HRP20151210T1 (hr) | 2015-12-04 |
US7931900B2 (en) | 2011-04-26 |
HUE026260T2 (en) | 2016-06-28 |
WO2005051422A1 (en) | 2005-06-09 |
EP1687026B1 (de) | 2008-05-14 |
CA2544920A1 (en) | 2005-06-09 |
JP2007511593A (ja) | 2007-05-10 |
AU2004292393C1 (en) | 2011-08-04 |
AU2004292393A1 (en) | 2005-06-09 |
CA2544920C (en) | 2012-09-11 |
EP1687026A1 (de) | 2006-08-09 |
EP1983000B1 (de) | 2015-09-02 |
DK1983000T3 (en) | 2015-12-07 |
PL1983000T3 (pl) | 2016-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE395083T1 (de) | Verfahren zur behandlung von multipler sklerose durch hemmung der il-17-aktivität | |
ATE416761T1 (de) | Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund | |
ATE520411T1 (de) | Behandlung und prävention von lungenerkrankungen | |
DE69815090D1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
DE602004030535D1 (de) | Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor-antagonisten und eines nsaid und diese enthaltende zusammensetzung | |
ATE250932T1 (de) | Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer | |
ATE321048T1 (de) | Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und - tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes | |
DE69924641D1 (de) | Behandlung von asthma anhand von mek-inhibitoren | |
ATE497778T1 (de) | Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus | |
ATE331527T1 (de) | Verfahren zur behandlung von brustdrüsenerkrankungen | |
ATE544449T1 (de) | Neue verwendung von peptidverbindungen zur behandlung von amyothropher lateralsklerose | |
ATE424208T1 (de) | Proteinkinaseinhibitoren | |
MX2024000271A (es) | Inhibidor de shp2 y uso del mismo. | |
DE60325717D1 (de) | Verfahren zur behandlung von angststörungen bei älteren personen | |
ATE497763T1 (de) | Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen | |
AU2019282132A8 (en) | Compositions and methods for treating pancreatitis | |
ATE287713T1 (de) | Verwendung von riluzol zur behandlung multipler sklerose | |
DE60144493D1 (de) | Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen | |
ATE334174T1 (de) | System und prozess zur reinigung und/oder behandlung von fahrzeugoberflächen | |
ATE409066T1 (de) | Einzeldosis aromatase hemmer zur behandlung von unfruchtbarkeit | |
DE602004022423D1 (de) | Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz | |
ATE542546T1 (de) | Pde 4 inhibitoren zur behandlung der interstitiellen cystitis | |
DE60327655D1 (de) | Verfahren zur behandlung von durch taxol induzierter sensorischer neuropathie | |
DE60327793D1 (de) | Modulation der s6-kinaseaktivität zur behandlung von adipositas | |
DE50210473D1 (de) | Phosphinat-peptidanaloga als inhibitoren der procollagen-c-proteinase (pcp) zur behandlung von fibrotischen erkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |